1534 ET - Eli Lilly's weight-loss pill slightly missed the company's efficacy expectations, but shares slid more than they should've, say UBS analysts. The pill led to 12.4% weight loss, which suggests it's still a viable drug. Consumers who want an oral GPL-1 drug may be willing to sacrifice some efficacy to avoid needles. The pill version will also cater to those looking to buy in cash, who value convenience over maximum efficacy, the analysts say. But the lower efficacy could lead Eli Lilly to offer the pill at a discount, which would hurt its potential boost to the company's earnings. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
August 08, 2025 15:34 ET (19:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。